EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT.
Merchant AA, Jorapur A, McManus A, Liu R, Krasnoperov V, Chaudhry P, Singh M, Harton L, Agajanian M, Kim M, Triche TJ Jr, Druker BJ, Tyner JW, Gill PS.
Merchant AA, et al. Among authors: liu r.
Blood Adv. 2017 Aug 28;1(20):1635-1644. doi: 10.1182/bloodadvances.2017005694. eCollection 2017 Sep 12.
Blood Adv. 2017.
PMID: 29296810
Free PMC article.